Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telcagepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 1/20 | 1.00 |
| ▸ | CALCA | P06881 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telcagepant SCHEMBL29371277 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL13345769 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3176473 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL32659727 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL13025488 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678266 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678268 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678042 | 0.99 | CALCRL (0.97) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678043 | 0.99 | CALCRL (0.97) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3682410 | 0.96 | CALCRL (0.92) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366286-A1 | COMPOUNDS FOR TREATING SEPSIS | Keller, Johannes (DE) | 2018-08-29 | — | — | EP | claimed |
| US-7829699-B2 | Process for the preparation of CGRP antagonist | MERCK SHARP & DOHME CORP. (US) | 2010-11-09 | — | — | US | claimed |
| US-20100009967-A1 | SOLID DOSAGE FORMULATIONS OF TELCAGEPANT POTASSIUM | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | claimed |
| WO-2010002763-A1 | SOLID DOSAGE FORMULATIONS OF TELCAGEPANT POTASSIUM | MERCK & CO., INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20090281306-A1 | efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1 -carboxamide; salt formation of potassium salt forms; treating migraine and cluster headache | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | claimed |
| EP-2007764-B1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | claimed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2022132989-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022109077-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210246137-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-12 | — | — | US | disclosed |
| WO-2020252368-A2 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20070225272-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-09-27 | — | — | US | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20050256098-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2005-11-17 | — | — | US | disclosed |
| US-6953790-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040229861-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, HSP90B1, CEP170 | CALCRL 4345/4885RAMP1 4602/4885CALCA 4095/4885 |
| US-20100009967-A1 | SOLID DOSAGE FORMULATIONS OF TELCAGEPANT POTASSIUM | KCNN1, KCNN2, KCNN3 | CALCRL 1126/4885RAMP1 2254/4885CALCA 2077/4885 |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | CALCB, CALCA, CALCRL | CALCRL 3/4885RAMP1 46/4885CALCA 2/4885 |
| US-20040229861-A1 | CGRP receptor antagonists | CCKBR, CCKAR, CALCRL | CALCRL 3/4885RAMP1 191/4885CALCA 21/4885 |
| US-20050256098-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CALCRL 6/4885RAMP1 187/4885CALCA 23/4885 |
| US-20070225272-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CALCRL 6/4885RAMP1 187/4885CALCA 23/4885 |
| US-20090281306-A1 | efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1 -carboxamide; salt formation of potassium salt forms; treating migraine and cluster headache | KCNJ2, KCNN2, KCNN1 | CALCRL 200/4885RAMP1 877/4885CALCA 181/4885 |
| US-20210246137-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | PLK1, HSP90B1, CEP170 | CALCRL 4345/4885RAMP1 4602/4885CALCA 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.